Danone Exceeds 2025 Sales Expectations, Eyes Strong 2026 Fueled by China's Baby Food Demand

Danone (EPA: BP) kicked off 2026 with strong momentum after surpassing its 2025 sales and cash flow forecasts. The French food group chalked up a 4.5% like-for-like sales increase, slightly ahead of analyst expectations, largely driven by soaring demand for baby food and medical nutrition in China.

The company's CEO, Antoine de Saint-Affrique, expressed cautious optimism despite acknowledging ongoing global uncertainties. He affirmed that Danone remains on track with its medium-term growth goal, signaling steady progress even as some regions face headwinds.

One significant spotlight has been the infant formula recalls related to contaminated products containing cereulide toxin. Danone said the current financial impact appears negligible, with the full scope to be determined once the recalls conclude. The company's exposure in China, where infant formula generates roughly 17% of its profits, contrasts with competitors like Nestlé, for whom this segment is less critical.

Danone's flagship brands such as Evian water and Activia yogurt continue to perform solidly, though challenges persist in more competitive markets like the U.S. coffee creamer segment. Nevertheless, the company managed to boost its recurring operating margin to 13.4% in 2025, up from 13% the year before, meeting market expectations.

Cash generation also beat consensus with €2.8 billion reported for 2025, giving Danone the confidence to announce a 4.7% dividend increase to €2.25 per share. This financial flexibility underscores the company's ability to navigate cost pressures while investing in growth markets.

After tightening prices aggressively during the inflation surge post-pandemic, Danone and peers including Unilever and Nestlé have pulled back on hikes to recapture price-sensitive consumers migrating to cheaper brands. This strategic move appears to help stabilize sales momentum, particularly in mature markets.

Looking forward, Danone projects steady underlying sales growth of 3-5% for 2026, with operating income expected to grow at a faster rate than sales. This aligns with its mid-term ambition to balance top-line growth with improved profitability amid volatile external factors.

Although the infant formula recall situation remains a watch point, particularly in relation to reputation risks in China's vital market, Danone's solid sales and margin results suggest resilience. It's a classic case of managing short-term disruption without losing sight of the bigger growth picture. Will the company keep this momentum going through 2026?